Modulation Therapeutics Incoporated
Modulation Therapeutics is developing a novel, first in class drug for multiple myeloma and other cancers that metastasize to bone.
The company is developing a novel first in class peptide mimetic drug called MT-101 for multiple myeloma and other cancers that metastasize to bone. MT-101 has a novel mechanism of action that differentiates it from all other existing drugs for myeloma. Preclinical data show promising single agent and combination (Velcade) efficacy with no overt toxicity in vivo. We seek investors to fund development of MT-101 from IND through Phase I/IIa.